|
Post by forthefuture on Dec 31, 2014 0:39:25 GMT
Just filed for an IPO. We are a leader in the field of gene therapy, seeking to transform the lives of patients suffering from debilitating genetic diseases by developing one-time, life-altering treatments. Our product candidates have the potential to provide long-lasting effects, dramatically and positively changing the lives of patients with conditions where no, or only palliative, therapies exist. Our initial focus is on treating orphan diseases, and we have demonstrated promising clinical outcomes with our first product candidate targeting rare blinding conditions, which has received both breakthrough therapy and orphan product designation and is in a fully enrolled, pivotal Phase 3 clinical trial with data expected in the second half of 2015. We also have built a pipeline of product candidates targeting additional blinding conditions, hematologic disorders and neurodegenerative diseases, including a second product candidate targeting another rare blinding condition, for which we expect to initiate a clinical trial in the first half of 2015, and a collaboration with Pfizer Inc., or Pfizer, for the development and commercialization of a gene therapy for the treatment of hemophilia B. Our platform technology is based on more than two decades of gene therapy research, development, manufacturing and clinical trials conducted at The Children’s Hospital of Philadelphia, or CHOP. S1 can be found here: www.sec.gov/Archives/edgar/data/1609351/000119312514457223/d776249ds1.htm
|
|
|
Post by darkest on Dec 31, 2014 19:01:13 GMT
GT is what it's all about lately. Why do we even need stem cells now?
|
|
|
Post by HeyNow on Dec 31, 2014 23:09:01 GMT
Can gene therapy cure nepotistic idiocy? That would be sweet
|
|
|
Post by Jimmywho on Jan 30, 2015 23:19:29 GMT
|
|
|
Post by forthefuture on Feb 2, 2015 17:24:16 GMT
I was hoping to get get in, but it just blasted way too fast out of the gate.
|
|